ORLANDO, Fla., May 14, 2015 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (‘Company,’ OTCQB symbol: ‘MDIT’ / OTCBB:MDIT), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces change of auditors.
